

Human-Pathogenic Kasokero Virus in Field-Collected Ticks

Amy J. Schuh, Brian R. Amman, Ketan Patel, Tara K. Sealy, Robert Swanepoel, Jonathan S. Towner

Kasokero virus (KASV; genus *Orthonairovirus*) was first isolated in 1977 at Uganda Virus Research Institute from serum collected from *Rousettus aegyptiacus* bats captured at Kasokero Cave, Uganda. During virus characterization studies at the institute, 4 laboratory-associated infections resulted in mild to severe disease. Although orthonairoviruses are typically associated with vertebrate and tick hosts, a tick vector of KASV never has been reported. We tested 786 *Ornithodoros (Reticulinasus) faini* tick pools (3,930 ticks) for KASV. The ticks were collected from a large *R. aegyptiacus* bat roosting site in western Uganda. We detected KASV RNA in 43 tick pools and recovered 2 infectious isolates, 1 of which was derived from host blood-depleted ticks. Our findings suggest that KASV is maintained in an enzootic transmission cycle involving *O. (R.) faini* ticks and *R. aegyptiacus* bats and has the potential for incidental virus spillover to humans.

The genus *Orthonairovirus* (family *Nairoviridae*) comprises ≈40 viruses (1), including human pathogens such as Crimean-Congo hemorrhagic fever virus. The orthonairoviruses are assigned to 14 species (1), most of which have been associated with a single vertebrate subphylum (Vertebrata: bats, birds, rodents, shrews, or ungulates) and tick order (Ixodida: argasids or ixodids) (2). The species *Kasokero orthonairovirus* comprises 3 viruses isolated from bats belonging to the suborder Yinpterochiroptera (3,4) (Pteropodiformes) (5) in Africa, namely Yogue virus (YOGV; *Rousettus aegyptiacus*, Senegal), Leopards Hill virus (LPHV; *Hipposideros gigas*, Zambia), and Kasokero virus (KASV; *Rousettus aegyptiacus*, Uganda) (2,6,7).

KASV was first isolated in 1977 by scientists at Uganda Virus Research Institute (UVRI) from 2.7% (2/74) of serum samples collected from *R. aegyptiacus*

bats captured at Kasokero Cave in Uganda (6). Two months after the KASV bat isolates were introduced to the UVRI laboratory and 3 weeks after the isolates were used in virus characterization assays, a laboratory staff member became ill. Shortly thereafter, 2 additional laboratory staff members became ill. Two of these laboratory staff members had participated in KASV characterization studies that involved virus antigen extraction and serologic testing; the third laboratory staff member had prepared KASV mouse brain suspensions for inoculation and examined virus-infected mice. Sixteen days after symptom onset in the index patient, a UVRI driver who reported no direct contact with the laboratory rooms used to handle the KASV isolates became ill. Manifestations ranged in severity from mild febrile illness to prolonged systemic disease characterized by fever, headache, myalgia, arthralgia, abdominal pain, nausea, diarrhea, chest pain, coughing, and hyperactive reflexes. Intracerebral inoculation of suckling mice with acute phase blood specimens collected from each of the 4 humans yielded a KASV isolate. KASV-specific antibodies were detected in serum from the 4 patients at various times after illness, as well as in 9.5% (10/105) of serum samples collected from other UVRI laboratory staff members and 67.6% (50/74) of the original *R. aegyptiacus* serum. In susceptibility studies, KASV killed suckling and adult mice by intracerebral and intraperitoneal inoculation within 8 days (6). In addition, nearly all naive adult mice that nursed KASV-inoculated suckling mice died of KASV infection, indicating horizontal transmission of virus infection.

The home range of *R. aegyptiacus* bats extends throughout sub-Saharan Africa; the bats prefer subterranean environments, such as caves or mines. At multiple locations, *Ornithodoros (Reticulinasus) faini* ticks (family Argasidae) (8) have been observed living within rock crevices and feeding on *R. aegyptiacus* bats (9–13). Although chiropteran ticks typically exhibit high host-specificity (9,14), miners, researchers, and other persons entering *R. aegyptiacus* bat roosts have reported being bitten by *O. (R.) faini* ticks (13).

Author affiliations: US Public Health Service Commissioned Corps, Rockville, Maryland, USA (A.J. Schuh); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A.J. Schuh, B.R. Amman, K. Patel, T.K. Sealy, J.S. Towner); University of Pretoria, Onderstepoort, South Africa (R. Swanepoel)

DOI: <https://doi.org/10.3201/eid2612.202411>

Because most orthonairoviruses have been associated with a tick host, *O. (R.) faini* ticks are likely to be involved in the enzootic transmission and maintenance of KASV and have the potential to be vectors for virus spillover into humans. In 1994 and 1995, KASV was isolated by 1 author (R.S.) from *O. (R.) faini* ticks collected in Lanner Gorge Cave (22.450°S, 31.150°E) in South Africa, where *R. aegyptiacus* bats roosted. The isolations were made by intracerebral inoculation of suckling mice and identified in cross-neutralization tests in mice using homologous and reference mouse antiserum and the prototype KASV UG Z-52969 isolate obtained from Yale Arbovirus Research Unit (New Haven, CT, USA) and methods described by Shope and Sather (15). At the time, KASV was considered a possible bunyavirus, and the isolations remained unpublished. No molecular studies were attempted, and the isolations are no longer available for sequencing. Members of the team that entered Lanner Gorge Cave were bitten by ticks, and in 2 team members, a moderately severe, transient febrile illness developed with headache, malaise, and myalgia a few days later; they refused to seek medical attention or to donate blood samples for virologic examination.

In this study, we tested 786 tick pools (3,930 total *O. [R.] faini* ticks) for KASV. We collected the ticks from a large *R. aegyptiacus* bat roosting site in western Uganda in 2013 and 2017.

Methods

Tick Collection and Processing

After obtaining approval from the Uganda Wildlife Authority, we collected adult and nymph *O. (R.) faini* ticks with forceps from rock crevices in Python Cave, Queen Elizabeth National Park, Uganda, over 4 days in April 2013 (12) and 1 day in September 2017. A chiropteran population consisting solely of $\approx 40,000$ *R. aegyptiacus* bats inhabit the cave (11). Ticks collected in 2013 were pooled in groups of 5, placed directly into grinding vials (OPS Diagnostics, <https://opsdiagnostics.com>) containing 250 μ L of a 1:1 ratio of MagMax Lysis Binding Solution Concentrate (Thermo Fisher Scientific, <https://www.thermofisher.com>) to 100% isopropanol (MagMax Lysis Binding Buffer) and then homogenized using the GenoGrinder 2000 (OPS Diagnostics). After we added 550 μ L of MagMax Lysis Binding Buffer, we transferred the tick pool lysates to cryovials and stored them under liquid nitrogen (12).

Ticks collected in 2017, also pooled in groups of 5, were placed directly into cryovials containing Dulbecco's Modified Eagle Medium supplemented with 20% heat-inactivated fetal bovine serum (FBS) and

antimicrobial drugs and then stored under liquid nitrogen. After thawing the tick pools, we transferred the contents to grinding vials, homogenized them using the GenoGrinder 2000, and then transferred them to a cryovial containing 250 μ L of Dulbecco's Modified Eagle Medium supplemented with 2% heat-inactivated FBS and antimicrobial drugs. We transferred a portion of each tick pool homogenate (100- μ L) into a 400- μ L aliquot of MagMax Lysis Binding Buffer.

RNA Extraction and Quantitative Reverse Transcriptase PCR

We extracted RNA (90 μ L) from the 2013 (800 μ L) and 2017 (500 μ L) tick pool lysates using the MagMax Pathogen RNA/DNA Kit on the MagMax Express-96 Deep Well Magnetic Particle Processor (Thermo Fisher Scientific). KASV has an 18.3-kb single-stranded, negative-sense, trisegmented RNA genome comprising large segment that encodes for the viral RNA-dependent RNA polymerase (RdRp), medium segment that encodes for the glycoprotein precursor (GP), and small segment that encodes for the nucleoprotein (N) (2). We analyzed RNA by quantitative reverse transcription PCR (qRT-PCR) using the SuperScript III Platinum One-Step qRT-PCR Kit (Thermo Fisher Scientific) with primers and probes (Appendix Table 1, <https://wwwnc.cdc.gov/EID/article/26/12/20-2411-App1.pdf>) targeting the KASV N gene, tick mitochondrial 16S ribosomal RNA (rRNA) gene (16), and eukaryotic 18S rRNA gene (Thermo Fisher Scientific; 2017 tick pools only). Relative KASV RNA copies/tick pool were interpolated from a standard curve generated from a serial dilution of a known concentration of a synthetic KASV RNA oligo.

KASV Infection Prevalence Calculations

We calculated maximum-likelihood estimates of KASV infection prevalence in individual ticks with exact 95% CIs using an online pooled prevalence calculator (<https://epitools.ausvet.com.au>). The calculator implemented a frequentist approach and assumed a fixed tick pool size ($n = 5$) and 100% KASV qRT-PCR sensitivity and specificity (17,18).

Virus Isolation and Immunofluorescence Assay

We attempted virus isolation on the four 2017 KASV RNA-positive tick pools. After clarifying the tick pool homogenates (650 μ L) by centrifugation, we transferred 200 μ L supernatant to a vial containing antimicrobials and incubated it at room temperature for 1 h. Monolayers of Vero E6 cells in 12-well plates were inoculated with 210 μ L of antimicrobial-treated supernatant and incubated for 1 h at 37°C under 5%

CO₂. After the addition of 1.3 mL maintenance media, cultures were incubated at 37°C under 5% CO₂ and monitored daily for cytopathic effect. After 7 d, we transferred 1 mL culture media to a cryovial and replaced with an equal volume of fresh maintenance media. We transferred a portion of the day 7 media (100 µL) into MagMax Lysis Binding Buffer (400 µL) for RNA extraction and qRT-PCR. After 9–10 d, tissue cultures monolayers that were KASV RNA positive at day 7 were scraped to release virus-infected cells. Part of each cellular medium (1 mL) was suspended in 5 mL of borate saline, and 100 µL was placed into MagMax Lysis Binding Buffer (400 µL) for RNA extraction and qRT-PCR. After the cell suspensions were pelleted by centrifugation, the borate saline was decanted, the cells were resuspended in 500 µL borate saline, and 12-well spot slides were spotted with 25 µL of the cellular suspensions. The slides were fixed in acetone before receiving 2 megarads of γ -irradiation.

Six spots on each slide were incubated with 25 µL of a 1:100 dilution of KASV mouse immune ascitic fluid (World Reference Center for Emerging Viruses and Arboviruses, <https://www.utmb.edu/gnl/research/wrceva>), and the other 6 spots were incubated with normal mouse ascitic fluid for 30 min at 37°C. After the incubation, the spot slides were rinsed 2 times with phosphate buffered saline (PBS), incubated with 24 µL of a 1:40 dilution of goat anti-mouse fluorescein isothiocyanate (MP Biomedicals, <https://www.mp-bio.com>) for 30 min at 37°C, rinsed with PBS, stained with Eriochrome Black T, rinsed with PBS, and then observed under a fluorescence microscope.

KASV Genome Sequencing

First-strand cDNA was synthesized directly from RNA extracted from 9 of the 2013 KASV RNA-positive tick pools using the qScript XLT cDNA SuperMix Kit (Quantabio, <https://www.quantabio.com>). KASV amplicons were generated from first-strand cDNA using the Q5 High-Fidelity 2X Master Mix (New England BioLabs, <https://www.neb.com>) and 6 multiplex pools of KASV-specific tiling primers (Appendix Table 2) that were designed using the Primal Scheme software (<http://primal.zibraproject.org>) (19). We prepared purified KASV amplicons for sequencing using the Accel-NGS 2S DNA Library Kit (Swift Biosciences, <https://swiftbiosci.com>). Indexed DNA libraries were pooled and then pair-end sequenced using a 500-cycle MiSeq Reagent Kit v2 on the MiSeq System (Illumina, <https://www.illumina.com>).

After thawing media collected from the two 2017 KASV isolates, we clarified the media by centrifugation and transferred 100 µL supernatant into 400 µL

TriPure Isolation Reagent (MilliporeSigma, <https://www.emdmillipore.com>). We extracted RNA from the KASV isolate lysates using the 5PRIME Phase Lock Gel (Quantabio) system and then purified it using the Monarch Total RNA Miniprep Kit (New England Biolabs). We prepared purified RNA for sequencing using the NEB rRNA Depletion and NEBNext Ultra II RNA Library Kits for Illumina (New England Biolabs). Indexed DNA libraries were pooled and then pair-end sequenced using a 300-cycle MiSeq Reagent Kit v2 on the MiSeq System (Illumina).

Sequence and Phylogenetic Analyses

KASV sequence data were imported into Geneious 11.1.2 (Biomatters, <https://www.geneious.com>). After removing KASV-specific primers from the sequences (2013 tick pools), we used BBDuk to trim adaptors and low-quality reads from both sequence ends (minimum quality 30). Long sequence reads were retained (>93% of maximum read length) and normalized to a target coverage level of 40 with a minimum depth of 2. Merged reads were mapped to the concatenated genome sequence of the KASV Z-52963 isolate using the Geneious mapper (minimum mapping quality 30), and consensus sequences were then extracted and parsed according to gene.

We used the MUSCLE algorithm (<https://www.ebi.ac.uk/Tools/msa/muscle>) to generate N, GP, and RdRp nucleotide and deduced amino acid alignments from the new KASV sequences and existing KASV, YOGV, and LPHV sequences. We constructed maximum-likelihood phylogenies using the PhyML 3.0 algorithm (20) in conjunction with the best-fit nucleotide substitution model (21) on the ATGC Montpellier Bioinformatics Platform (<http://www.atgc-montpellier.fr>). We visualized phylogenies using TreeGraph 2 (<http://treegraph.bioinfweb.info>) (22). We estimated the global ratio of the rate of nonsynonymous (d_N) nucleotide substitutions to the rate of synonymous (d_S) nucleotide substitutions ($d_N:d_S$) across the KASV nucleotide alignments using the fixed effects likelihood method with the HyPhy version 1.8.2 software (<https://www.hyphy.org>).

Results

Description of the *O. (R.) faini* Tick Collections

We collected 3,125 *O. (R.) faini* ticks (625 pools of 5 each) from the rock crevices within *R. aegyptiacus* bat roosting sites in Python Cave, Uganda, in 2013 and 975 *O. (R.) faini* ticks (195 pools of 5 each) from the same location in 2017. We confirmed the *O. (R.) faini* species designation by comparative genetic analysis

of the 16S rRNA gene of a set of ticks and by morphologic examination (12). Screening the *O. (R.) faini* tick pools for the tick-specific 16S rRNA gene revealed that 4.3% (27/625) of the 2013 pools and 3.6% (7/195) of the 2017 pools were negative, indicating that these samples contained RNA inhibitors and were unsuitable for downstream KASV qRT-PCR analysis.

Detection of KASV RNA in Ticks

We detected KASV RNA in 39/598 of the 2013 *O. (R.) faini* tick pools and 4/188 of the 2017 *O. (R.) faini* tick pools, resulting in maximum-likelihood estimates of KASV infection prevalence at the individual tick level of 1.34% (95% CI 0.94%–1.83%) and 0.43% (95% CI 0.12%–1.10%), respectively. Based off a standard curve using synthetic KASV RNA, the mean KASV load of the positive 2013 tick pools was 5.5 (range 0.6–7.0) \log_{10} RNA copies, and the mean KASV load of the positive 2017 tick pools was 7.1 (range 1.5–7.6) \log_{10} RNA copies (Figure 1).

Isolation of Infectious KASV from Ticks

We isolated infectious KASV from 50% (2/4) of the 2017 KASV RNA-positive tick pools. As expected, the 2 KASV isolates were derived from the tick pools with the highest KASV RNA loads (UGA-Tick-20170048: 7.6 \log_{10} RNA copies and UGA-Tick-20170128: 7.0 \log_{10} RNA copies) (Figure 1). A qRT-PCR targeting the eukaryotic 18S rRNA gene was used to screen the KASV-isolation positive tick pools for *R. aegyptiacus* blood. We found no trace of *R. aegyptiacus* blood in tick pool UGA-Tick-20170048, indicating that the 5 ticks in this pool had not recently taken a blood meal from an actively KASV-infected *R. aegyptiacus* bat. This finding suggests that KASV in this tick pool resulted from active virus replication in ≥ 1 tick.

Circulation of Genetically Diverse KASVs

We attempted genomic sequencing on 9 of the 2013 KASV RNA-positive tick pools with KASV loads ≥ 3.6 \log_{10} RNA copies and on the two 2017 KASV tick isolates. We obtained complete sequence coverage for the N (1,545 nt) for 11 of the KASV-positive tick pools, the GP (4,314 nt) for 4 of the KASV-positive tick pools, and the RdRp (11,919 nt) genes for 4 of the KASV-positive tick pools. Maximum-likelihood phylogenies constructed from N, GP, and RdRp gene sequences from the 2013 and 2017 KASV-positive tick pools, as well as prototype KASV (Z-52963, *R. aegyptiacus*, Uganda, 1977), YOGV (DakAnD 56, *R. aegyptiacus*, Senegal, 1968), and LPHV (11SB17, *H. gigas*, Zambia, 2011) isolate sequences, had similar topologies and virus species groupings (Figure 2). Consistent with




Figure 1. Kasokero virus RNA loads in *Ornithodoros (Reticulinasus) faini* tick pools from *Rousettus aegyptiacus* bats, western Uganda, 2013 and 2017. Black horizontal bars represent mean viral loads.

previous results (2,23,24), YOGV diverged first followed by LPHV, and finally the KASV lineage. The N phylogeny showed 2 distinct KASV lineages defined by $>9.2\%$ interlineage nucleotide divergences, and the RdRp phylogeny showed 2 distinct KASV lineages defined by $\geq 12.0\%$ interlineage nucleotide divergences; the first lineage included the prototype Z-52963 sequence plus the 2013 tick sequences and the second lineage included the 2017 tick sequences (Appendix Tables 3, 4). Deduced amino acid alignments of the N and RdRp proteins revealed that most KASV lineage-defining nucleotide substitutions were synonymous with interlineage amino acid divergences ranging from 0.6% to 1.0% for the N protein and 2.4% to 2.6% for the RdRp protein. In contrast to the N and RdRp phylogenies, the GP phylogeny shows that the Z-52963 sequence diverged first, followed by the divergence of the 2013 and the 2017 tick sequence groups. Furthermore, the KASV sequences in the GP phylogeny are considerably more similar to one another at the nucleotide level ($\leq 2.2\%$ nt divergence and $\leq 0.9\%$ aa divergence) and do not form 2 distinct lineages (Appendix Table 5). Consistent with the phylogenetic and KASV gene/protein divergence data, $d_N:d_S$ estimates demonstrated that the N gene was under the strongest purifying selection (0.0110), followed by the RdRp (0.0264) and GP (0.0650) genes.

Discussion

We detected KASV RNA in 43 *O. (R.) faini* tick pools collected from a large *R. aegyptiacus* bat colony at Python Cave, Uganda, over a 4-year span. The mean KASV RNA load for the 39 positive 2013 tick pools stored in MagMax Lysis Binding Buffer was lower (5.5 [range 0.6–7.0] \log_{10} RNA copies) than the 4 positive 2017 tick

pools stored in sterile media supplemented with FBS and antimicrobial drugs (7.1 [range 1.5–7.6] log₁₀ RNA copies). Although this difference might have resulted from the choice of sample preservation buffer, it could also be attributed to the type of storage vial (internally threaded for 2017 ticks vs. externally threaded for 2013 ticks), number of RNA freeze-thaw cycles (0 for 2017 ticks vs. 1 for 2013 ticks), month of tick collection in relation to the natural history of KASV infection in *O. (R.) faini* ticks (September for ticks collected in 2017 vs. April for ticks collected in 2013), or sample size effect (39 KASV-positive tick pools in 2013 vs. 4 KASV-positive tick pools in 2017). We could not attempt virus isolation on the 2013 KASV-positive tick pools because they were placed directly in virucidal buffer; however, we isolated infectious KASV from 2 of the 2017 KASV RNA-positive tick pools. Importantly, molecular evidence of *R. aegyptiacus* blood was not detected in 1 of the KASV isolation-positive tick pools. This finding

indicates that the presence of infectious KASV in this tick pool resulted from active virus replication in ≥ 1 tick and not from ingestion of a recent blood meal by a tick feeding on a viremic *R. aegyptiacus* bat. Although we did not assess whether KASV can disseminate to the salivary glands of *O. (R.) faini* ticks and then be successfully transmitted to *R. aegyptiacus* bats, our data coupled with the results of a previous study demonstrating a 2.7% prevalence of active KASV infection and a 67.6% KASV seroprevalence in *R. aegyptiacus* captured at Kasokero Cave, Uganda (6), suggest that this virus is maintained in an enzootic transmission cycle involving *R. aegyptiacus* bats and *O. (R.) faini* ticks. The isolation of KASV from *O. (R.) faini* ticks collected from a *R. aegyptiacus* bat roost in Lanner Gorge Cave, South Africa, in 1994–1995 (R. Swanepoel, unpub. data) supports this notion and suggests that KASV has a widespread geographic distribution. Tick transmission of KASV also is consistent with our knowledge




Figure 2. Maximum-likelihood phylogenies constructed from virus sequences belonging to the species *Kasokero orthonairovirus*, including viruses collected from *Ornithodoros (Reticulinasus) faini* tick pools from *Rousettus aegyptiacus* bats, western Uganda, 2013 and 2017. The midpoint rooted phylogenies were generated from complete nucleoprotein (N) (A), glycoprotein precursor (GP) (B), and RNA-dependent RNA-polymerase (RdRp) (C) gene sequences. The N and RdRp gene phylogenies were generated using the general time-reversible nucleotide substitution model with the addition of invariant sites, and the GP gene phylogeny was generated using the general time-reversible nucleotide substitution model with a gamma distribution of rates across sites. Horizontal branch lengths are proportional to the genetic distance between the sequences. Numbers at the end of the branches represent percent bootstrap values based on 1,000 replicates. Only percent bootstrap values $\geq 50\%$ are shown. GenBank accession numbers for the new Kasokero virus tick sequences from this study are MT309080–98. Scale bars indicate nucleotide substitutions per site.

of the vector status of the orthonairoviruses (2). Of the 14 currently recognized orthonairovirus species (1), 13 have now been associated with a tick host.

Genetic analysis of the KASV nucleotide alignment showed that the N and RdRp gene sequences were highly divergent, whereas the GP gene sequences were highly conserved. However, the low $d_N:d_S$ estimates, together with the high level of conservation between the deduced amino acid sequences for the N, GP, and RdRp proteins, suggest that strong purifying selection purged deleterious mutations. This finding is consistent with findings of previous studies demonstrating that arbovirus evolution is constrained to enable alternating infection of disparate vertebrate and arthropod hosts (25–27).

Additional work is needed to fully understand the roles that *R. aegyptiacus* bats and *O. (R.) faini* ticks play in maintaining KASV over time (9). Collection and separation of *O. (R.) faini* ticks according to life history stage, as well as experimental tick work, will be important in determining whether these ticks serve as amplification or reservoir hosts for KASV. Detection of infectious KASV in larval, nymphal, and adult stages of *O. (R.) faini* ticks would suggest that the virus is transstadially transmitted, and ticks serve as virus amplification hosts. Likewise, detection of KASV in nymphs and adults originating from KASV-artificially infected *O. (R.) faini* larvae would suggest the virus is transtadially transmitted from one generation to the next. Isolation of KASV in *O. (R.) faini* eggs found in nature or in larvae originating from KASV-artificially infected female ticks would indicate that the virus is transovarially transmitted and that ticks are reservoir hosts for the virus because a vertebrate host is not required for long-term virus survival. Similarly, a longitudinal ecologic investigation of KASV infection in *R. aegyptiacus* bats, as well as experimental KASV infection of captive bats, is critical in defining the relationship this virus has with its vertebrate host. Although KASV has previously been isolated from 2 wild-caught *R. aegyptiacus* bats (6), the isolation of actively replicating KASV over several days in experimentally infected *R. aegyptiacus* bats will confirm the ability of this bat species to serve as an amplification host for the virus. The detection of KASV in oral, rectal, or urogenital shedding collected from experimentally infected or wild-caught *R. aegyptiacus* bats will not only provide evidence that these bats are reservoir hosts of the virus but also indicate that they are capable of transmitting the virus to humans that encroach upon their habitat.

Although no human cases of KASV infection have been reported since the initial UVRI-associated cases described in 1977 (6), surveillance of populations at

risk for KASV infection has never been conducted. Miners, herders, tourists, and researchers often frequent mines and caves occupied by large colonies of *R. aegyptiacus* bats. Entry into *R. aegyptiacus* bat-inhabited environments has been linked to the spillover of several pathogenic agents into the human population, including Marburg virus (11,28,29), Sosuga virus (30,31), and *Borrelia* spirochetes (13). Similarly, humans who enter environments occupied by *R. aegyptiacus* bats and *O. (R.) faini* ticks are likely to be at risk for KASV infection. Surveillance of these at-risk populations for evidence of active or past infection KASV infection is needed to determine the true burden of KASV infection in humans.

Acknowledgments

We thank Margret Driciru and the Uganda Wildlife Authority rangers at Python Cave in Queen Elizabeth National Park for providing support during the tick collections and Shannon Whitmer for providing Illumina sequencing advice. We are grateful to Kenneth Plante, Scott Weaver, Nikos Vasilakis, Robert Tesh, and Thomas Ksiazek for providing the KASV Z-52963 isolate and KASV mouse immune ascitic fluid from the World Reference Center for Emerging Viruses and Arboviruses.

This work was funded in part through an interagency agreement with the Defense Threat Reduction Agency, HDTRA16-025-33037.

About the Author

Dr. Schuh is a research scientist with the Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention. Her research interests include investigating the enzootic transmission dynamics of tickborne and batborne viruses and identifying ecologic drivers underlying the spillover of zoonotic viruses into the human population.

References

1. Maes P, Adkins S, Alkhovsky SV, Avšič-Županc T, Ballinger MJ, Bente DA, et al. Taxonomy of the order *Bunyavirales*: second update 2018. Arch Virol. 2019;164:927–41. <https://doi.org/10.1007/s00705-018-04127-3>
2. Walker PJ, Widen SG, Firth C, Blasdell KR, Wood TG, Travassos da Rosa AP, et al. Genomic characterization of Yogue, Kasokero, Issyk-Kul, Keterah, Gossas, and Thiafora viruses: nairoviruses naturally infecting bats, shrews, and ticks. Am J Trop Med Hyg. 2015;93:1041–51. <https://doi.org/10.4269/ajtmh.15-0344>
3. Springer MS. Phylogenetics: bats united, microbats divided. Curr Biol. 2013;23:R999–1001. <https://doi.org/10.1016/j.cub.2013.09.053>

4. Lei M, Dong D. Phylogenomic analyses of bat subordinal relationships based on transcriptome data. *Sci Rep*. 2016;6:27726. <https://doi.org/10.1038/srep27726>
5. Hutcheon JM, Kirsch JAW. A moveable face: deconstructing the Microchiroptera and a new classification of extant bats. *Acta Chiropt*. 2006;8:1–10. [https://doi.org/10.3161/1733-5329\(2006\)8\[1:AMFDTM\]2.0.CO;2](https://doi.org/10.3161/1733-5329(2006)8[1:AMFDTM]2.0.CO;2)
6. Kalunda M, Mukwaya LG, Mukuye A, Lule M, Sekyalo E, Wright J, et al. Kasokero virus: a new human pathogen from bats (*Rousettus aegyptiacus*) in Uganda. *Am J Trop Med Hyg*. 1986;35:387–92. <https://doi.org/10.4269/ajtmh.1986.35.387>
7. Ishii A, Ueno K, Orba Y, Sasaki M, Moonga L, Hang'ombe BM, et al. Aairovirus isolated from African bats causes haemorrhagic gastroenteritis and severe hepatic disease in mice. *Nat Commun*. 2014;5:5651. <https://doi.org/10.1038/ncomms6651>
8. Mans BJ, Featherston J, Kvas M, Pillay K-A, de Klerk DG, Pienaar R, et al. Argasid and ixodid systematics: implications for soft tick evolution and systematics, with a new argasid species list. *Ticks Tick Borne Dis*. 2019;10:219–40. <https://doi.org/10.1016/j.ttbdis.2018.09.010>
9. Hoogstraal H. Argasid and nuttalliellid ticks as parasites and vectors. *Adv Parasitol*. 1985;24:135–238. [https://doi.org/10.1016/S0065-308X\(08\)60563-1](https://doi.org/10.1016/S0065-308X(08)60563-1)
10. Braack LEO. Arthropod inhabitants of a tropical cave 'island' environment provisioned by bats. *Biol Conserv*. 1989;48:77–84. [https://doi.org/10.1016/0006-3207\(89\)90027-X](https://doi.org/10.1016/0006-3207(89)90027-X)
11. Amman BR, Carroll SA, Reed ZD, Sealy TK, Balinandi S, Swanepoel R, et al. Seasonal pulses of Marburg virus circulation in juvenile *Rousettus aegyptiacus* bats coincide with periods of increased risk of human infection. *PLoS Pathog*. 2012;8:e1002877. <https://doi.org/10.1371/journal.ppat.1002877>
12. Schuh AJ, Amman BR, Apanaskevich DA, Sealy TK, Nichol ST, Towner JS. No evidence for the involvement of the argasid tick *Ornithodoros faini* in the enzootic maintenance of Marburgvirus within Egyptian rousette bats *Rousettus aegyptiacus*. *Parasit Vectors*. 2016;9:128. <https://doi.org/10.1186/s13071-016-1390-z>
13. Qiu Y, Nakao R, Hang'ombe BM, Sato K, Kajihara M, Kanchela S, et al. Human borreliosis caused by a New World relapsing fever *Borrelia*-like organism in the Old World. *Clin Infect Dis*. 2019;69:107–12. <https://doi.org/10.1093/cid/ciy850>
14. Sándor AD, Corduneanu A, Péter Á, Mihalca AD, Barti L, Csósz I, et al. Bats and ticks: host selection and seasonality of bat-specialist ticks in eastern Europe. *Parasit Vectors*. 2019;12:605. <https://doi.org/10.1186/s13071-019-3861-5>
15. Shope RE, Sather GE. Diagnostic procedures for viral, rickettsial and chlamydial infections. In: Schmidt NJ, Lennette EH, editors. *Arboviruses*. 5th ed. Washington (DC): American Public Health Association; 1979. p. 767–814.
16. Shone SM, Dillon HJ, Hom SS, Delgado N. A novel real-time PCR assay for the speciation of medically important ticks. *Vector Borne Zoonotic Dis*. 2006;6:152–60. <https://doi.org/10.1089/vbz.2006.6.152>
17. Cowling DW, Gardner IA, Johnson WO. Comparison of methods for estimation of individual-level prevalence based on pooled samples. *Prev Vet Med*. 1999;39:211–25. [https://doi.org/10.1016/S0167-5877\(98\)00131-7](https://doi.org/10.1016/S0167-5877(98)00131-7)
18. Andreassen A, Jore S, Cuber P, Dudman S, Tengs T, Isaksen K, et al. Prevalence of tick borne encephalitis virus in tick nymphs in relation to climatic factors on the southern coast of Norway. *Parasit Vectors*. 2012;5:177. <https://doi.org/10.1186/1756-3305-5-177>
19. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. *Nat Protoc*. 2017;12:1261–76. <https://doi.org/10.1038/nprot.2017.066>
20. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. *Syst Biol*. 2010;59:307–21. <https://doi.org/10.1093/sysbio/syq010>
21. Lefort V, Longueville JE, Gascuel O. SMS: Smart Model Selection in PhyML. *Mol Biol Evol*. 2017;34:2422–4. <https://doi.org/10.1093/molbev/msx149>
22. Stöver BC, Müller KF. TreeGraph 2: combining and visualizing evidence from different phylogenetic analyses. *BMC Bioinformatics*. 2010;11:7. <https://doi.org/10.1186/1471-2105-11-7>
23. Walker PJ, Widen SG, Wood TG, Guzman H, Tesh RB, Vasilakis N. A global genomic characterization of nairoviruses identifies nine discrete genogroups with distinctive structural characteristics and host-vector associations. *Am J Trop Med Hyg*. 2016;94:1107–22. <https://doi.org/10.4269/ajtmh.15-0917>
24. Aguilar PV, Marciel de Souza W, Silvas JA, Wood T, Widen S, Fumagalli MJ, et al. Genetic characterization of the Patois serogroup (genus *Orthobunyavirus*; family *Peribunyaviridae*) and evidence that Estero Real virus is a member of the genus *Orthonairovirus*. *Am J Trop Med Hyg*. 2018;99:451–7. <https://doi.org/10.4269/ajtmh.18-0201>
25. Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, Weaver SC. Arbovirus evolution in vivo is constrained by host alternation. *Proc Natl Acad Sci U S A*. 2008;105:6970–5. <https://doi.org/10.1073/pnas.0712130105>
26. Vasilakis N, Dearnorff ER, Kenney JL, Rossi SL, Hanley KA, Weaver SC. Mosquitoes put the brake on arbovirus evolution: experimental evolution reveals slower mutation accumulation in mosquito than vertebrate cells. *PLoS Pathog*. 2009;5:e1000467. <https://doi.org/10.1371/journal.ppat.1000467>
27. Grubaugh ND, Rückert C, Armstrong PM, Bransfield A, Anderson JF, Ebel GD, et al. Transmission bottlenecks and RNAi collectively influence tick-borne flavivirus evolution. *Virus Evol*. 2016;2:vev033. <https://doi.org/10.1093/ve/vev033>
28. Swanepoel R, Smit SB, Rollin PE, Formenty P, Leman PA, Kemp A, et al.; International Scientific and Technical Committee for Marburg Hemorrhagic Fever Control in the Democratic Republic of Congo. Studies of reservoir hosts for Marburg virus. *Emerg Infect Dis*. 2007;13:1847–51. <https://doi.org/10.3201/eid1312.071115>
29. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. *PLoS Pathog*. 2009; 5:e1000536. <https://doi.org/10.1371/journal.ppat.1000536>
30. Amman BR, Albariño CG, Bird BH, Nyakarahuka L, Sealy TK, Balinandi S, et al. A recently discovered pathogenic paramyxovirus, Sosuga virus, is present in *Rousettus aegyptiacus* fruit bats at multiple locations in Uganda. *J Wildl Dis*. 2015;51:774–9. <https://doi.org/10.7589/2015-02-044>
31. Albariño CG, Foltzer M, Towner JS, Rowe LA, Campbell S, Jaramillo CM, et al. Novel paramyxovirus associated with severe acute febrile disease, South Sudan and Uganda, 2012. *Emerg Infect Dis*. 2014;20:211–6. <https://doi.org/10.3201/eid2002.131620>

Address for correspondence: Jonathan S. Towner, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H18-B, Atlanta, GA 30329-4027, USA; email: jit8@cdc.gov

Human-Pathogenic Kasokero Virus in Field-Collected Ticks

Appendix

Appendix Table 1. Quantitative reverse transcriptase PCR primers and probes

Assay	Oligo name	Sequence, 5'–3'
KASV N, 105-bp amplicon	Forward primer	GGACATTGACTCTCAGACTTC
	Reverse primer	GTCCAGGCACACTCATAAAT
	Probe	56-FAM-AGCAGTCAT-ZEN-CGCAGCCACCAGAAA-3IABkFQ
Shone tick 16S rRNA	Forward primer	CTGCTCAATGATTTTTTAAATTGCTGTGGT
	Reverse primer	CCGGTCTGAACTCAGATCAAGTAGGA
	Probe	6FAM-AAATAGTTTGCACCTCGATGTTGGATTAGGAT-BHQ1
Applied Biosystems Eukaryotic 18S rRNA Endogenous Control Kit (VIC®/TAMRA probe, primer limited), Thermo Fisher Scientific	Not available	Not available

Appendix Table 2. Kasokero virus–specific tiling primers for genome amplification

Oligo name	Sequence, 5'–3'	Pool no.
KASV_S_1_LEFT	CAAAGACAGACGTGCCGCTTAC	1
KASV_S_1_RIGHT	AGAATCTGTTCCAGCCTCAGGCA	1
KASV_S_3_LEFT	AGGAAGAAAAGACTTGGTGGTGT	1
KASV_S_3_RIGHT	GACTCTCCCTGTGCAACACTTG	1
KASV_S_5_LEFT	TCGTTTGCAAGCTCCAATTTTAAACG	1
KASV_S_5_RIGHT	TATTTGGGGCAGCAACAACGTT	1
KASV_S_2_LEFT	GAACGATCCATGACCTGGTTCA	2
KASV_S_2_RIGHT	GCTCGATTTGCTATCAAGCCA	2
KASV_S_4_LEFT	ATGAGTGAGGATGCTGCCAAGA	2
KASV_S_4_RIGHT	TGCAACTGGGAATGCTCCAAG	2
KASV_S_6_LEFT	ATCCCTGTGCCTCTATGGTGAC	2
KASV_S_6_RIGHT	ATGTTGCCGCATACCCCAATTT	2
KASV_M_1_LEFT	AAAGAAAGACTTGCGGCTACCC	3
KASV_M_1_RIGHT	CCGTTGGCCATTTGGAGTACAG	3
KASV_M_3_LEFT	ACATGGAAATCGACAATCTGGCA	3
KASV_M_3_RIGHT	GGCAACCTTTTCAATTTGGACGT	3
KASV_M_5_LEFT	TGTCCACTTCGTGATTGAGAGAAA	3
KASV_M_5_RIGHT	TGACCCAACTCTATAGCAGCCA	3
KASV_M_7_LEFT	AGGTCCAGCTGAAACACTGTCT	3
KASV_M_7_RIGHT	AATTGACCATGTCGTTGACGCT	3
KASV_M_9_LEFT	ATCAGAAGGACACCTAGGCTGG	3
KASV_M_9_RIGHT	GTATGTGCAGTGTCCCAAGG	3
KASV_M_11_LEFT	GCAGGTTGAGTACATAACGGG	3
KASV_M_11_RIGHT	TGCAATTCTTTGGGAGCAGT	3
KASV_M_13_LEFT	ATGCATTAGTCTTTGATGACATTACAAGT	3
KASV_M_13_RIGHT	AAATTGCGAGTGAAACCTGGCA	3
KASV_M_15_LEFT	CTGTGTTGGCCTGGAACCTGAA	3
KASV_M_15_RIGHT	CAGAAAGGCTTTCTCCTCTGCC	3
KASV_M_2_LEFT	TGGGTGGAAATAAAAACCTGGAGTGA	4
KASV_M_2_RIGHT	GCAAACCTCTGTCCTTGAGGCA	4
KASV_M_4_LEFT	GCCACTACCAAAGGTACCACCA	4
KASV_M_4_RIGHT	CTTCTCTGCAAACCATGTGCCT	4
KASV_M_6_LEFT	ACAAGTCATTTCCAGATGCCAAAGT	4
KASV_M_6_RIGHT	AGTGAAGTCTGTGCTGTTTGCC	4
KASV_M_8_LEFT	GCATCACTCTGCAGGTCCTTTC	4
KASV_M_8_RIGHT	AGAGCAGGACTACAAACCACGT	4
KASV_M_10_LEFT	TGAACCGTCAAAGAACCTCACA	4

Oligo name	Sequence, 5'-3'	Pool no.
KASV_M_10_RIGHT	ATCATCGCAGCCACAGTTCTTG	4
KASV_M_12_LEFT	AGTTTGTGAAGTCGTGGAAGCG	4
KASV_M_12_RIGHT	GTGCATGTTGTCCAGTCTCCAG	4
KASV_M_14_LEFT	AGAGCTGAATTCACAAAAGGTTAACC	4
KASV_M_14_RIGHT	CTCCCCCTTCACAGGTCTGATT	4
KASV_M_16_LEFT	AGCTTCCTCAGACTGTTCAAGAGA	4
KASV_M_16_RIGHT	AGATATAGTGGCGGCTTACCCT	4
KASV_L_1_LEFT	CAAAGAAAGTAATCCCCCATATCCAGA	5
KASV_L_1_RIGHT	TTGCATTGTTACCCAGACACC	5
KASV_L_3_LEFT	CACTTTCCAAGAGGAGCTGGAC	5
KASV_L_3_RIGHT	TTAGTTCACCCGGTGACCACAAC	5
KASV_L_5_LEFT	AGCATAGACAAAAGACAGCTGCT	5
KASV_L_5_RIGHT	TCCGCAATATCCTTCCGTCTGA	5
KASV_L_7_LEFT	GGACACCGAGCAGCTTTCAATT	5
KASV_L_7_RIGHT	AAATCCTTGAGCGGCACATCAG	5
KASV_L_9_LEFT	TGCCGTGCAAGAAGTAAGTTCA	5
KASV_L_9_RIGHT	TCTCAGAAGGCGAGTTTTCAAGT	5
KASV_L_11_LEFT	TTGAAGTCTCGCTGGTAGAGGG	5
KASV_L_11_RIGHT	GGTTGGGCATCCTTCGTTCAA	5
KASV_L_13_LEFT	CAAGCAATAAACTGCCGACTGG	5
KASV_L_13_RIGHT	TGTCATTCTGCACTTTGAAGTTGGA	5
KASV_L_15_LEFT	ACTTTGAGTGGTACCAACAGCA	5
KASV_L_15_LEFT_NEW	ACTTTGAGTGGTACCAGCAGCA	5
KASV_L_15_RIGHT	ACCCCAAGCTTCTCTTCATGCT	5
KASV_L_15_RIGHT_NEW	ACCCCAAGCTTCTCTTCATGTT	5
KASV_L_17_LEFT	TGACGTACTCCTAGGTGATAGTATGC	5
KASV_L_17_LEFT_NEW	TGACGTACTACTAGGTGATAGTATAC	5
KASV_L_17_RIGHT	TCAGCAGTTTCTTCCAACCT	5
KASV_L_17_RIGHT_NEW	TCAGCAGTTTCTTCTAACACCT	5
KASV_L_19_LEFT	AAAGGCAGCAAGGTCTTTCAGG	5
KASV_L_19_RIGHT	TCATGGACCTAGGTTTCAGCAACA	5
KASV_L_21_LEFT	TCAAAGCTAACCTTCTACAACCTGGAA	5
KASV_L_21_RIGHT	AGAGCCCTTCTTCCCAATCTCT	5
KASV_L_23_LEFT	TGTCCTGGTGTGTGCAGTATA	5
KASV_L_23_RIGHT	GAGGAAGCCTTTCACCATTGCT	5
KASV_L_25_LEFT	GTCACAGAGACTTGTTGGTCCA	5
KASV_L_25_RIGHT	TGCTGCTGGTATTTCCACTTGC	5
KASV_L_27_LEFT	TGCCACGTCTTCAGTTCTCACT	5
KASV_L_27_RIGHT	CATGCCTGCACGAGACTCAAAG	5
KASV_L_29_LEFT	CTCTATGTCCCCAAGTTTAGTGGTT	5
KASV_L_29_LEFT_NEW	CTCTATGTCCCCAAGTTTCAGTGGCT	5
KASV_L_29_RIGHT	AATCTTTCTGATGCACGGGCTG	5
KASV_L_31_LEFT	GCTTCTTCCAGAAAAGCTCAGGA	5
KASV_L_31_RIGHT	TTTACCGTCAAGCACCTTTCCG	5
KASV_L_33_LEFT	TGAGTCAGAAACAAGAAGTCTGGC	5
KASV_L_33_RIGHT	ACACAAGACAGTCAAGTTATTCGCA	5
KASV_L_35_LEFT	TGCGTTTCAGCAATTTCTGTTATGC	5
KASV_L_35_RIGHT	TCCTGATGAGTCACCTGAGCTG	5
KASV_L_37_LEFT	AGCAAAGATGACCCAAAACCTACTAAGT	5
KASV_L_37_RIGHT	GTGTGTGAGCCAGGAAGTGATG	5
KASV_L_39_LEFT	CGAAAGAGGAGTTGATCTGTGCC	5
KASV_L_39_RIGHT	TCTGACTACGGGCAATGACTGT	5
KASV_L_41_LEFT	GGATCGAACTAACCAAGGTGCG	5
KASV_L_41_RIGHT	CCGACAGGTTCTTTCACCTCTT	5
KASV_L_2_LEFT	ATACTGGGGAGGCTCGGTAGAA	6
KASV_L_2_RIGHT	AAGTGTCTCCTCCTCGTCCATG	6
KASV_L_4_LEFT	GCATTTGACATAAATTCACCTGGGCA	6
KASV_L_4_RIGHT	GCATAACGACCTCCTGCACAAG	6
KASV_L_6_LEFT	GTGTGTCTTTGGTTGTGAAATTGCA	6
KASV_L_6_RIGHT	ACGGCTTATAGAGTTCGGCACA	6
KASV_L_8_LEFT	CCATCCAAACGGTGTTTCCTGA	6
KASV_L_8_RIGHT	GCCTGCTTTCTTTCCTGCTGAT	6
KASV_L_10_LEFT	CGCACTGACTGGTGGATTGATG	6
KASV_L_10_RIGHT	TCCTTGATGATGCTACCGCTCT	6
KASV_L_12_LEFT	TTGAAAACCTTCTCTGAAAAGCTGACAT	6
KASV_M_12_LEFT_NEW	AGT TTG TGA AGT TGT GGA GGC A	6
KASV_L_12_RIGHT	AGTGTCTTGGTGCCTCCTCTTT	6
KASV_L_14_LEFT	AACATCCATTATGACTTGGGATCAGA	6
KASV_L_14_RIGHT	TGAGCACCTTAATTCCTGCCCT	6

Oligo name	Sequence, 5'-3'	Pool no.
KASV_L_16_LEFT	TTGCAGTGCCTACAACACTACA	6
KASV_L_16_RIGHT	TGGACAGGACATTCTGCTCAGA	6
KASV_L_18_LEFT	TCAATAGCGACAGACAATTGATATTTGAT	6
KASV_L_18_RIGHT	GACCTCCAGCGTTTCAGTAAGG	6
KASV_L_20_LEFT	CCCTCCTGAATCAATCGAGAAAGC	6
KASV_L_20_RIGHT	TTGTGCCAATGACTTCAGCCAG	6
KASV_L_22_LEFT	AAAGACCTTGATGAGCGGGAGA	6
KASV_L_22_RIGHT	GCAGTCTCTCAGTGAGGTCGA	6
KASV_L_22_RIGHT_NEW	GCA GTT CTC TTA GTG AAG TTG A	6
KASV_L_24_LEFT	AGGATTGGATGATTCAAGATCTGATTCA	6
KASV_L_24_RIGHT	TGTGTGTTTCGTCAAACCATCATCT	6
KASV_L_26_LEFT	AGTGAATGATGCAGCAACTATTGA	6
KASV_L_26_RIGHT	CAGCATGTGTCACAGTCACCTG	6
KASV_L_28_LEFT	TCATGATGTCTCAGAGAATAACCCCT	6
KASV_L_28_RIGHT	TCAGGTAGATGGAGCATCAGCC	6
KASV_L_30_LEFT	AAGCCAGCAGTTTTCTAGTGGT	6
KASV_L_30_RIGHT	AGAGTGTCACTTGAGCAGGGTT	6
KASV_L_32_LEFT	ACCACTTTACACCATTTTTATGAAGTCTT	6
KASV_L_32_RIGHT	TAACGGCTTTGTGTGCATCCAG	6
KASV_L_34_LEFT	CGTTAGTGAACCTTATAAACGAGATAAACA	6
KASV_L_34_LEFT_NEW	CGTTAGTGAACCTTAATGAGATAAATAATG	6
KASV_L_34_RIGHT	AGGGCAATTACTGTCACACTCAG	6
KASV_L_34_RIGHT_NEW	AGG GCA ATC ACT GTC ACA CTC AG	6
KASV_L_36_LEFT	AAACCCTGTTTAGGCACAACCG	6
KASV_L_36_RIGHT	TGAACTCTTCAGCTGCCTTCT	6
KASV_L_38_LEFT	AGTTTATGAAGACACAAGGATAGTGCT	6
KASV_L_38_RIGHT	TGAACCCGGTTTCATCCAGGTA	6
KASV_L_40_LEFT	TGCAGAAATGTAATCAGTAGGACTGG	6
KASV_L_40_RIGHT	TTCATAAGCTCCCTCCACAGCA	6
KASV_L_42_LEFT	GGAAAGAAAACATCAAGCTCTTGCA	6
KASV_L_42_RIGHT	ATACGAATGTTTGCCCTGCCAA	6

Appendix Table 3. Pairwise comparisons of *Kasokero orthonairovirus* nucleoprotein sequences*

Virus	1†	2	3	4	5	6	7	8	9	10	11	12	13	14
1		29.2	26.8	27.5	27.4	27.5	27.5	27.5	27.5	27.5	27.5	27.5	27.2	27.1
2	22.1		21.6	22.0	22.1	22.0	22.0	22.0	22.0	22.0	22.0	22.0	21.3	21.3
3	21.9	9.9		1.7	1.8	1.7	1.7	1.7	1.7	1.7	1.7	1.7	9.5	9.4
4	21.9	10.3	0.4		0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.3	9.2
5	21.9	10.3	0.4	0.0		0.1	0.2	0.1	0.1	0.1	0.1	0.1	9.3	9.2
6	21.9	10.3	0.4	0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	9.3	9.2
7	21.9	10.3	0.4	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0	9.3	9.2
8	21.9	10.3	0.4	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	9.3	9.2
9	21.9	10.3	0.4	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	9.3	9.2
10	21.9	10.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	9.3	9.2
11	21.9	10.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	9.3	9.2
12	21.9	10.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		9.3	9.2
13	22.2	9.9	0.6	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0		0.1
14	22.2	9.9	0.6	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	0.0	

*Upper diagonal: % nucleotide divergence; Lower diagonal: % amino acid divergence.

†1: Dak AnD 56 (Yogues virus), 2: 11SB17 (Leopards Hill virus), 3: Z-52963 (Kasokero virus; KASV), 4: UGA-Tick-20130490 (KASV), 5: UGA-Tick-20130501 (KASV), 6: UGA-Tick-20130502 (KASV), 7: UGA-Tick-20130503 (KASV), 8: UGA-Tick-20130508 (KASV), 9: UGA-Tick-20130514 (KASV), 10: UGA-Tick-20130524 (KASV), 11: UGA-Tick-20130525 (KASV), 12: UGA-Tick-20130533 (KASV), 13: UGA-Tick-20170048 (KASV), 14: UGA-Tick-20170128 (KASV).

Appendix Table 4. Pairwise comparisons of *Kasokero orthonairovirus* glycoprotein precursor sequences*

Virus	1†	2	3	8	12	13	14
1		38.4	38.7	38.5	38.5	38.4	38.4
2	39.6		34.3	34.3	34.3	34.3	34.4
3	39.5	31.9		2.2	2.2	2.1	2.1
8	39.5	31.8	0.9		0.0	0.6	0.6
12	39.5	31.8	0.9	0.0		0.6	0.6
13	39.5	31.8	0.8	0.3	0.3		0.2
14	39.5	31.8	0.8	0.3	0.3	0.0	

*Upper diagonal: % nucleotide divergence; Lower diagonal: % amino acid divergence.

†1: Dak AnD 56 (Yogues virus), 2: 11SB17 (Leopards Hill virus), 3: Z-52963 (Kasokero virus; KASV), 8: UGA-Tick-20130508 (KASV), 12: UGA-Tick-20130533 (KASV), 13: UGA-Tick-20170048 (KASV), 14: UGA-Tick-20170128 (KASV).

Appendix Table 5. Pairwise comparisons of *Kasokero orthonairovirus* RNA-dependent RNA-polymerase sequences*

Virus	1†	2	3	8	12	13	14
1		31.2	30.3	30.4	30.3	30.5	30.5
2	23.9		26.9	26.8	26.7	26.7	26.7
3	23.1	16.1		2.2	2.1	12.1	12.2
8	23.2	16.1	0.7		0.1	12.1	12.1
12	23.1	16.0	0.6	0.2		12.0	12.0
13	23.2	15.9	2.6	2.5	2.4		0.1
14	23.2	15.9	2.5	2.5	2.4	0.1	

*Upper diagonal: % nucleotide divergence; Lower diagonal: % amino acid divergence.

†1: Dak AnD 56 (Yogue virus), 2: 11SB17 (Leopards Hill virus), 3: Z-52963 (Kasokero virus; KASV), 8: UGA-Tick-20130508(KASV) , 12: UGA-Tick-20130533 (KASV), 13: UGA-Tick-20170048 (KASV), 14: UGA-Tick-20170128 (KASV).